Search

Objective: Child sleep problems are commonly reported by parents of children aged 6--18 years, with a growing body of evidence describing the link between children's screen time and parental perceived child sleep problems. Using cross-sectional data, representative of the Victorian population, this study explored whether the relationship between screen time and parental perceived sleep problems differed across child age groups. It also examined whether parental rules moderated this relationship differentially between primary school-aged children and adolescents. Method: Participants were 1699 parents living in Victoria with children aged 6 to 18 years who were recruited to complete a computer assisted personal communication through random dialling of mobile and landline numbers. Results: Results indicated that more screen time was associated with more parental perceived sleep problems, with parental rules moderating this relationship for primary school-aged children but not for adolescents. Contrary to expectations, the relationship between screen time and parental perceived sleep problems did not differ across child age groups. Conclusions: Results suggest that parental rules on media device use may be an instrumental factor in the development of successful intervention programmes for primary school-aged children. Further implications of these findings and suggestions for future research are discussed.

Ice shelf calving constitutes roughly half of the total mass loss from the Antarctic ice sheet. Although much attention is paid to calving of giant tabular icebergs, these events are relatively rare. Here, we investigate the role of frontal melting and stresses at the ice shelf front in driving bending and calving on the scale of ∼100 m, perpendicular to the ice edge. We focus in particular on how buoyant underwater “feet” that protrude beyond the above-water ice cliff may cause tensile stresses at the base of the ice. Indirect and anecdotal observations of such feet at the Ross Ice Shelf front suggest that the resulting bending may be widespread and can trigger calving. We consider satellite observations together with an elastic beam model and a parameterization of wave erosion to better understand the dynamics at the ice shelf front. Our results suggest that on average frontal ablation rather consistently accounts for 20±5 m yr−1 of ice loss at Ross Ice Shelf, likely mostly due to wave erosion and smaller-scale, 𝒪(100 m), foot-induced calving. This constitutes only ∼2 % of the total frontal mass loss (since near-front ice velocities are ∼1000 m yr−1). Observational evidence suggests that sporadic larger events can skew this rate (we document one foot-induced calving event of size ∼1 km). Stresses from foot-induced bending are likely not sufficient to initiate crevassing but rather act to propagate existing crevasses. In addition, our results support recent findings by Buck (2024) that additional bending moments, likely due to temperature gradients in the ice, may play a role in driving frontal deflections. The highly variable environment, irregularity of pre-existing crevasse spacing, and complex rheology of the ice continue to pose challenges in better constraining the drivers behind the observed deformations and resulting calving rates.

The prolongation of survival along with the preservation of quality of life, possibly avoiding harmful cumulative toxicities, is the primary therapeutic aim for patients with metastatic colorectal cancer (mCRC) in the third-line setting. Several therapeutic options are now available, although some differences across countries in drug approval and the optimal therapeutic sequencing associated with each peculiar patient subgroup represent a clinical challenge for oncologists. Among various options, the SUNLIGHT trial showed how the combination of trifluridine/tipiracil (FTD/TPI) with bevacizumab is effective with an easily manageable toxicity profile compared to FTD/TPI alone. Of note, the efficacy is confirmed independently from KRAS mutational status and also for patients who had breaks in anti-vascular endothelial growth factor (anti-VEGF) therapy. Herein, we describe the current state of the art in the landscape of treatments after the second progression in mCRC. Based on a critical review of the literature aimed to guide clinicians in their daily decision-making, we point out that the combination of FTD/TPI with bevacizumab produces a clinical benefit in unselected mCRC patients. Therefore, the FTD/TPI plus bevacizumab regimen can represent a new standard of care for the treatment of patients with refractory mCRC who have progressed after two lines of therapy.

The prolongation of survival along with the preservation of quality of life, possibly avoiding harmful cumulative toxicities, is the primary therapeutic aim for patients with metastatic colorectal cancer (mCRC) in the third-line setting. Several therapeutic options are now available, although some differences across countries in drug approval and the optimal therapeutic sequencing associated with each peculiar patient subgroup represent a clinical challenge for oncologists. Among various options, the SUNLIGHT trial showed how the combination of trifluridine/tipiracil (FTD/TPI) with bevacizumab is effective with an easily manageable toxicity profile compared to FTD/TPI alone. Of note, the efficacy is confirmed independently from KRAS mutational status and also for patients who had breaks in anti-vascular endothelial growth factor (anti-VEGF) therapy. Herein, we describe the current state of the art in the landscape of treatments after the second progression in mCRC. Based on a critical review of the literature aimed to guide clinicians in their daily decision-making, we point out that the combination of FTD/TPI with bevacizumab produces a clinical benefit in unselected mCRC patients. Therefore, the FTD/TPI plus bevacizumab regimen can represent a new standard of care for the treatment of patients with refractory mCRC who have progressed after two lines of therapy. [ABSTRACT FROM AUTHOR]

Ice shelf calving constitutes roughly half of the total mass loss from the Antarctic ice sheet. Although much attention is paid to calving of giant tabular icebergs, these events are relatively rare. Here, we investigate the role of frontal melting and stresses at the ice shelf front in driving bending and calving on the scale of ∼100 m, perpendicular to the ice edge. We focus in particular on how buoyant underwater "feet" that protrude beyond the above-water ice cliff may cause tensile stresses at the base of the ice. Indirect and anecdotal observations of such feet at the Ross Ice Shelf front suggest that the resulting bending may be widespread and can trigger calving. We consider satellite observations together with an elastic beam model and a parameterization of wave erosion to better understand the dynamics at the ice shelf front. Our results suggest that on average frontal ablation rather consistently accounts for 20±5 m yr−1 of ice loss at Ross Ice Shelf, likely mostly due to wave erosion and smaller-scale, O (100 m), foot-induced calving. This constitutes only ∼2 % of the total frontal mass loss (since near-front ice velocities are ∼1000 m yr−1). Observational evidence suggests that sporadic larger events can skew this rate (we document one foot-induced calving event of size ∼1 km). Stresses from foot-induced bending are likely not sufficient to initiate crevassing but rather act to propagate existing crevasses. In addition, our results support recent findings by that additional bending moments, likely due to temperature gradients in the ice, may play a role in driving frontal deflections. The highly variable environment, irregularity of pre-existing crevasse spacing, and complex rheology of the ice continue to pose challenges in better constraining the drivers behind the observed deformations and resulting calving rates. [ABSTRACT FROM AUTHOR]

Dysglycemia is a condition preceding diabetes mellitus. The two situations inherent in this condition are called impaired fasting glucose (IFG) and impaired glucose tolerance (IGT). If one of these situations is found in the patient, after the advice of an appropriate diet and physical activity, the addition of nutraceuticals or supplements can be considered, which can stop or delay the progression to diabetes mellitus over time. The purpose was to compile a systematic review about the use of nutraceuticals for treating diabetes and prediabetes and to offer a valuable resource for colleagues working on this crucial subject, thereby improving patient health. The added value of the paper compared to other reviews is that it was written by experts appointed by five different scientific societies dealing with diabetes, nutrition, and complications. [ABSTRACT FROM AUTHOR]

Background: Methylthioadenosine phosphorylase (MTAP) is an essential metabolic enzyme in the purine and methionine salvage pathway. In cancer, MTAP gene copy number loss ( MTAP loss) confers a selective dependency on the related protein arginine methyltransferase 5. The impact of MTAP alterations in gastrointestinal (GI) cancers remains unknown although hypothetically druggable. Here, we aim to investigate the prevalence, clinicopathological features and prognosis of MTAP loss GI cancers., Methods: Cases with MTAP alterations were retrieved from The Cancer Genome Atlas (TCGA) and a real-world cohort of GI cancers profiled by next-generation sequencing. If MTAP alterations other than loss were found, immunohistochemistry was performed. Finally, we set a case-control study to assess MTAP loss prognostic impact., Results: Findings across the TCGA dataset (N=1363 patients) and our cohort (N=508) were consistent. Gene loss was the most common MTAP alteration (9.4%), mostly co-occurring with CDKN2A/B loss (97.7%). Biliopancreatic and gastro-oesophageal cancers had the highest prevalence of MTAP loss (20.5% and 12.7%, respectively), being mostly microsatellite stable (99.2%). In colorectal cancer, MTAP loss was rare (1.1%), while most MTAP alterations were mutations (5/7, 71.4%); among the latter, only MTAP-CDKN2B truncation led to protein loss, thus potentially actionable. MTAP loss did not confer worse prognosis., Conclusions: MTAP alterations are found in 5%-10% of GI cancers, most frequently biliopancreatic and gastro-oesophageal. MTAP loss is the most common alteration, identified almost exclusively in MSS, CDKN2A/B loss, upper-GI cancers. Other MTAP alterations were found in colorectal cancer, but unlikely to cause protein loss and drug susceptibility., Competing Interests: Competing interests: AB reports personal fees from Guardant Health and Inivata during the conduct of the study as well as grants from AstraZeneca, Boehringer-Ingelheim and Neophore outside the submitted work; in addition, AB is a shareholder of Neophore and Kither. SS is an advisory board member for Agenus, AstraZeneca, Bayer, BMS, CheckmAb, Daiichi-Sankyo, Guardant Health,Merck, Novartis, Roche-Genentech and Seagen. AS-B reports personal fees from Amgen, Bayer, Servier, Guardant Health and Novartis during the conduct of the study. GMauri and GP received honoraria from COR2ED., (© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY. Published by BMJ Group.)